AN ACT CONCERNING PRESCRIPTION DRUG SHORTAGES, PRESCRIPTION DRUG REBATES AND PROHIBITED MANUFACTURER PRACTICES CONCERNING CERTAIN PRESCRIPTION DRUGS.
FILE NO. 483
Email me when SB 494 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SB 494. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill establishes a bipartisan prescription‑drug task force with defined membership, term limits and administrative support to identify drugs at risk of shortage and recommend mitigation strategies. It directs the Economic and Community Development commissioner to add drug‑shortage prevention to the Strategic Supply Chain Initiative, and it requires the Social Services commissioner to negotiate higher supplemental rebates from drug manufacturers and report on rebate activity. The measures aim to improve drug availability and reduce costs for Connecticut’s medical assistance programs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SB 494
3 free questions a day, no accountHistory
- SENATE CALENDAR NUMBER 295
- RPTD. OUT OF LCO
- FILE NO. 483
- FAV. RPT., TAB. FOR CAL., SEN.
- REFERRED TO Office of Legislative Research AND Office of Fiscal Analysis 04/07/26
- FILED WITH LCO
- Joint Favorable Substitute
- PUBLIC HEARING 0317
- REF. TO JOINT COMM. ON Human Services
Sponsors
- Martin Looney (D) · sponsor
- Martin M. Looney
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SB 494 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SB 494 freeOr ask your AI assistant about SB 494 directly:
Add to Claude, ChatGPT or Cursor